European Neuropsychopharmacology最新文献

英文中文

Mitochondrial DNA copy number is significantly increased in bipolar disorder patients and is correlated with long-term lithium treatment 双相情感障碍患者线粒体DNA拷贝数显著增加，且与长期锂治疗相关

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2024-11-28 DOI: 10.1016/j.euroneuro.2024.10.012

Anna Meloni , Pasquale Paribello , Marco Pinna , Martina Contu , Raffaella Ardau , Caterina Chillotti , Donatella Congiu , Massimo Gennerelli , Alessandra Minelli , Lisa Buson , Giovanni Severino , Claudia Pisanu , Mirko Manchia , Alessio Squassina

Mitochondrial dysfunctions have been reported in bipolar disorder (BD), but their role in the etiopathogenesis of BD as well as their implications in modulating response to pharmacological treatments with psychotropic medications have been scarcely explored. Mitochondrial DNA copy number (mtDNA-cn) has been linked to mitochondria functioning, and, despite some degree of inconsistence, previous findings showed that BD patients present significant differences in mtDNA-cn compared to healthy controls. Here we measured mtDNA-cn in a sample of 89 patients with BD and 78 healthy controls (HC). Patients in the BD sample were treated either with lithium (n = 47) and characterized as responders (n = 22) or non-responders (n = 25), or with other mood stabilizers (n = 42). BD patients had larger mtDNA-cn compared to HC (adjusted model: F₂=9.832; p = 0.000095; contribution of diagnosis F₁= 10.798; p = 0.001). When the BD sample was stratified for treatment exposure, mtDNA-cn was lower in patients treated with lithium compared to those treated with other mood stabilizers (adjusted model: F₄=23.770, p = 7.0929E-13; contribution of treatment: F₁=54.300, p = 1.55E-10). Moreover mtDNA-cn was higher in patients treated with other mood stabilizers compared to controls and Li-treated BD patients (F₃=28.125, p = 1.36E-14; contribution of groups F₂=36.156, p = 1.25E-13). Finally, there was no difference in mtDNA-cn levels in lithium responders compared to non-responders and neither between the two diagnostic groups (BD type 1 and 2). Our findings suggest that BD may be associated with mitochondrial dysfunctions, and that exposure to lithium but not to other mood stabilizers may restore these abnormalities, though this does not appear correlated with the clinical efficacy of lithium.

线粒体功能障碍在双相情感障碍（BD）中已有报道，但其在双相情感障碍发病机制中的作用以及在调节精神药物药物治疗反应中的意义却很少被探讨。线粒体DNA拷贝数（mtDNA-cn）与线粒体功能有关，尽管存在一定程度的不一致，但先前的研究结果表明，与健康对照组相比，BD患者的mtDNA-cn存在显著差异。在这里，我们测量了89名BD患者和78名健康对照（HC）的mtDNA-cn样本。BD样本中的患者接受锂治疗（n = 47），并被定性为有反应（n = 22）或无反应（n = 25），或使用其他情绪稳定剂（n = 42）。BD患者的mtDNA-cn比HC患者大(调整模型：F2=9.832；P = 0.000095；诊断贡献率F1= 10.798；P = 0.001)。当对BD样本进行分层治疗暴露时，锂治疗组患者的mtDNA-cn低于其他心境稳定剂治疗组(调整模型：F4=23.770, p = 7.0929E-13；治疗贡献：F1=54.300, p = 1.55E-10)。此外，与对照组和li治疗的BD患者相比，使用其他情绪稳定剂治疗的患者mtDNA-cn更高(F3=28.125, p = 1.36E-14；F2=36.156, p = 1.25E-13)。最后，与无反应者相比，锂反应者的mtDNA-cn水平没有差异，两个诊断组（BD 1型和2型）之间也没有差异。我们的研究结果表明，BD可能与线粒体功能障碍有关，暴露于锂而不是其他情绪稳定剂可能会恢复这些异常，尽管这似乎与锂的临床疗效无关。

{"title":"Mitochondrial DNA copy number is significantly increased in bipolar disorder patients and is correlated with long-term lithium treatment","authors":"Anna Meloni , Pasquale Paribello , Marco Pinna , Martina Contu , Raffaella Ardau , Caterina Chillotti , Donatella Congiu , Massimo Gennerelli , Alessandra Minelli , Lisa Buson , Giovanni Severino , Claudia Pisanu , Mirko Manchia , Alessio Squassina","doi":"10.1016/j.euroneuro.2024.10.012","DOIUrl":"10.1016/j.euroneuro.2024.10.012","url":null,"abstract":"<div><div>Mitochondrial dysfunctions have been reported in bipolar disorder (BD), but their role in the etiopathogenesis of BD as well as their implications in modulating response to pharmacological treatments with psychotropic medications have been scarcely explored. Mitochondrial DNA copy number (mtDNA-cn) has been linked to mitochondria functioning, and, despite some degree of inconsistence, previous findings showed that BD patients present significant differences in mtDNA-cn compared to healthy controls. Here we measured mtDNA-cn in a sample of 89 patients with BD and 78 healthy controls (HC). Patients in the BD sample were treated either with lithium (<em>n</em> = 47) and characterized as responders (<em>n</em> = 22) or non-responders (<em>n</em> = 25), or with other mood stabilizers (<em>n</em> = 42). BD patients had larger mtDNA-cn compared to HC (adjusted model: F<sub>2</sub>=9.832; <em>p</em> = 0.000095; contribution of diagnosis F<sub>1</sub>= 10.798; <em>p</em> = 0.001). When the BD sample was stratified for treatment exposure, mtDNA-cn was lower in patients treated with lithium compared to those treated with other mood stabilizers (adjusted model: F<sub>4</sub>=23.770, <em>p</em> = 7.0929E-13; contribution of treatment: F<sub>1</sub>=54.300, <em>p</em> = 1.55E-10). Moreover mtDNA-cn was higher in patients treated with other mood stabilizers compared to controls and Li-treated BD patients (F<sub>3</sub>=28.125, <em>p</em> = 1.36E-14; contribution of groups F<sub>2</sub>=36.156, <em>p</em> = 1.25E-13). Finally, there was no difference in mtDNA-cn levels in lithium responders compared to non-responders and neither between the two diagnostic groups (BD type 1 and 2). Our findings suggest that BD may be associated with mitochondrial dysfunctions, and that exposure to lithium but not to other mood stabilizers may restore these abnormalities, though this does not appear correlated with the clinical efficacy of lithium.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"Pages 37-44"},"PeriodicalIF":6.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cannabis use and psychosis: evidence and new clinical features of a new epidemic 大麻使用和精神病：一种新流行病的证据和新的临床特征

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2024-11-28 DOI: 10.1016/j.euroneuro.2024.11.007

Giovanni Martinotti , Marta Di Forti

引用次数: 0

Optimizing differential diagnostics and identifying transdiagnostic treatment targets using virtual reality 利用虚拟现实优化鉴别诊断和识别跨诊断治疗目标

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2024-11-28 DOI: 10.1016/j.euroneuro.2024.11.006

Hanne Lie Kjærstad , Andreas Elleby Jespersen , Johanne Lilmose Bech , Sofie Weidemann , Anne Juul Bjertrup , Emilie Hestbæk Jacobsen , Sebastian Simonsen , Louise Birkedal Glenthøj , Merete Nordentoft , Kristian Reveles , Tine Wøbbe , Mads Lopes , Daniel Lyngholm , Kamilla Woznica Miskowiak

Accurate diagnosis in psychiatry remains a significant challenge, often delaying appropriate treatment and resulting in poorer clinical outcomes. Identifying precise biomarkers for differential diagnosis is therefore crucial. This study aimed to identify distinct behavioral and psychophysiological markers of emotional reactivity in virtual reality (VR) settings among individuals with bipolar disorder (BD), borderline personality disorder (BPD), schizophrenia spectrum disorders (SSD), and healthy controls (HC). Participants (BD: n = 32, BPD: n = 21, SSD: n = 17, HC: n = 30) aged 19–60 were exposed to six immersive 360-degree social VR scenarios, ranging from neutral to highly emotional contexts (e.g., an elevator ride, a crying baby). Emotional responses were self-rated on a 1–5 scale, while galvanic skin response (GSR) was continuously recorded. Scenarios assessed feelings of unpleasantness, pleasantness, being observed, and the urge to comfort. Across diagnoses, individuals with mental health conditions reported more negative emotional responses (greater unpleasantness) across both neutral and negative scenarios (ps ≤ 0.02) despite similar GSR levels to HC. Specifically, in the elevator scenario, BPD and SSD experienced greater unpleasantness and feelings of being observed, coupled with stronger GSRs compared to BD (ps ≤ 0.03). SSD reported higher unpleasantness in the canteen scenario, less pleasantness in the happy baby scenario, and overall higher GSR than BD (ps ≤ 0.049). Negative emotional reactivity was consistent across BD, BPD, and SSD, with heightened emotional and physiological responses distinguishing SSD and BPD from BD in specific VR contexts. VR-based assessments of emotional and physiological markers show promise for improving differential diagnosis and identifying transdiagnostic treatment targets.

精神病学的准确诊断仍然是一项重大挑战，经常延误适当的治疗并导致较差的临床结果。因此，确定精确的生物标志物用于鉴别诊断至关重要。本研究旨在确定双相情感障碍（BD）、边缘型人格障碍（BPD）、精神分裂症谱系障碍（SSD）和健康对照（HC）患者在虚拟现实（VR）环境下情绪反应的不同行为和心理生理标志物。年龄在19-60岁的参与者（BD: n = 32, BPD: n = 21, SSD: n = 17, HC: n = 30）被暴露在6个沉浸式360度社交VR场景中，从中性到高度情绪化的场景（例如乘坐电梯，哭泣的婴儿）。情绪反应自评1-5级，同时连续记录皮肤电反应（GSR）。情景评估了不愉快的感觉、愉快的感觉、被观察的感觉和安慰的冲动。在诊断过程中，尽管与HC的GSR水平相似，但有精神健康状况的个体在中性和消极情景中都报告了更多的消极情绪反应（更大的不愉快）（ps≤0.02）。具体而言，在电梯场景中，BPD和SSD体验到更大的不愉快和被观察的感觉，并且gsr比BD更强（ps≤0.03）。SSD在食堂场景中报告的不愉快程度更高，在快乐婴儿场景中报告的不愉快程度更低，总体上的GSR高于BD （ps≤0.049）。负面情绪反应在BD、BPD和SSD中是一致的，在特定的VR环境中，SSD和BPD与BD之间的情绪和生理反应增强。基于vr的情绪和生理指标评估有望改善鉴别诊断和确定跨诊断治疗目标。

{"title":"Optimizing differential diagnostics and identifying transdiagnostic treatment targets using virtual reality","authors":"Hanne Lie Kjærstad , Andreas Elleby Jespersen , Johanne Lilmose Bech , Sofie Weidemann , Anne Juul Bjertrup , Emilie Hestbæk Jacobsen , Sebastian Simonsen , Louise Birkedal Glenthøj , Merete Nordentoft , Kristian Reveles , Tine Wøbbe , Mads Lopes , Daniel Lyngholm , Kamilla Woznica Miskowiak","doi":"10.1016/j.euroneuro.2024.11.006","DOIUrl":"10.1016/j.euroneuro.2024.11.006","url":null,"abstract":"<div><div>Accurate diagnosis in psychiatry remains a significant challenge, often delaying appropriate treatment and resulting in poorer clinical outcomes. Identifying precise biomarkers for differential diagnosis is therefore crucial. This study aimed to identify distinct behavioral and psychophysiological markers of emotional reactivity in virtual reality (VR) settings among individuals with bipolar disorder (BD), borderline personality disorder (BPD), schizophrenia spectrum disorders (SSD), and healthy controls (HC). Participants (BD: <em>n</em> = 32, BPD: <em>n</em> = 21, SSD: <em>n</em> = 17, HC: <em>n</em> = 30) aged 19–60 were exposed to six immersive 360-degree social VR scenarios, ranging from neutral to highly emotional contexts (e.g., an elevator ride, a crying baby). Emotional responses were self-rated on a 1–5 scale, while galvanic skin response (GSR) was continuously recorded. Scenarios assessed feelings of unpleasantness, pleasantness, being observed, and the urge to comfort. Across diagnoses, individuals with mental health conditions reported more negative emotional responses (greater unpleasantness) across both neutral and negative scenarios (<em>p</em>s ≤ 0.02) despite similar GSR levels to HC. Specifically, in the elevator scenario, BPD and SSD experienced greater unpleasantness and feelings of being observed, coupled with stronger GSRs compared to BD (<em>p</em>s ≤ 0.03). SSD reported higher unpleasantness in the canteen scenario, less pleasantness in the happy baby scenario, and overall higher GSR than BD (<em>p</em>s ≤ 0.049). Negative emotional reactivity was consistent across BD, BPD, and SSD, with heightened emotional and physiological responses distinguishing SSD and BPD from BD in specific VR contexts. VR-based assessments of emotional and physiological markers show promise for improving differential diagnosis and identifying transdiagnostic treatment targets.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"92 ","pages":"Pages 1-9"},"PeriodicalIF":6.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142745071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rare Genetic variation in schizophrenia: Are the most obvious ‘druggable pathways’ hiding in plain sight? 精神分裂症的罕见遗传变异：最明显的“可药物途径”是否隐藏在人们的视线中？

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2024-11-28 DOI: 10.1016/j.euroneuro.2024.11.010

Mark Ainsley Colijn

引用次数: 0

Valproate's impact on future generations — A call for stricter guidelines for maternal and paternal use 丙戊酸对后代的影响——呼吁对母亲和父亲的使用制定更严格的指导方针

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2024-11-28 DOI: 10.1016/j.euroneuro.2024.11.005

Meritxell González-Campos , Helena Andreu , Oscar De Juan , Luis Olivier , Gerard Anmella

引用次数: 0

Clinical sleep staging for insomnia disorder 失眠障碍的临床睡眠分期

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2024-11-28 DOI: 10.1016/j.euroneuro.2024.11.009

Christophe Gauld , Tessa Blanken

引用次数: 0

Corrigendum to “Lung function decline in people with serious mental illness: A call to action” [European Neuropsychopharmacology (2024) 41-46/ ENP-24-342] 严重精神疾病患者肺功能下降：行动呼吁"[欧洲神经精神药理学（2024）41-46/ ENP-24-342]。

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2024-11-22 DOI: 10.1016/j.euroneuro.2024.11.004

Cristina Ruiz-Rull , María José Jaén-Moreno , Gloria Isabel del Pozo , Cristina Camacho-Rodríguez , Marta Rodríguez-López , Fernando Rico-Villademoros , José Luis Otero-Ferrer , Nuria Feu , Micaela Reyes-López , Rosa M. Fiestas , David Laguna-Muñoz , Ana Jiménez-Peinado , David Mannino , Eduard Vieta , Fernando Sarramea

引用次数: 0

The need for specific mental health interventions for the prevention of suicide in postpandemic times 有必要采取特定的心理健康干预措施，以预防流行病后时期的自杀。

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2024-11-14 DOI: 10.1016/j.euroneuro.2024.10.007

Alejandro de la Torre-Luque , Jose Luis Ayuso-Mateos

引用次数: 0

Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review 轻微大麻素对精神疾病的治疗潜力：系统综述。

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2024-11-13 DOI: 10.1016/j.euroneuro.2024.10.006

Guido Cammà , Monika P. Verdouw , Pim B. van der Meer , Lucianne Groenink , Albert Batalla

Interest in cannabinoids’ therapeutic potential in mental health is growing, supported by evidence of the involvement of the endocannabinoid system in psychiatric disorders such as anxiety, depression, and addiction. While the major cannabinoids cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC) have been more extensively researched, approximately 120 minor cannabinoids from the cannabis plant have been identified. Although some displayed promising pharmacological profiles, research on their application for psychiatric disorders is fragmented. This systematic review evaluates, for the first time, both preclinical and clinical studies exploring minor cannabinoids’ therapeutic potential in psychiatric disorders.

22 preclinical studies and one clinical study were included, investigating various minor cannabinoids in substance use disorders, anxiety disorders, depressive disorders, trauma and stressor-related disorders, psychotic disorders, neurodevelopmental disorders, and eating disorders. Despite the heterogeneous results and the moderate to high risk of bias in several articles, certain compounds demonstrate promise for further investigation. Δ8-tetrahydrocannabidivarin (Δ8‐THCV) exhibited potential for nicotine addiction; Δ9-tetrahydrocannabidivarin (Δ9‐THCV) for psychotic-like symptoms; cannabidiolic acid methyl ester (CBDA-ME) alleviated anxiety and depression-like symptoms, and cannabidivarin (CBDV) autism spectrum disorder-like symptoms.

有证据表明，内源性大麻素系统参与了焦虑、抑郁和成瘾等精神疾病的治疗，因此人们对大麻素在精神健康方面的治疗潜力越来越感兴趣。虽然对主要大麻素大麻二酚（CBD）和Δ9-四氢大麻酚（Δ9-THC）的研究更为广泛，但从大麻植物中发现的次要大麻素约有 120 种。虽然其中一些大麻素显示出良好的药理学特征，但有关其在精神疾病方面应用的研究却很零散。本系统性综述首次评估了探索次生大麻素对精神疾病治疗潜力的临床前和临床研究。其中包括 22 项临床前研究和 1 项临床研究，这些研究调查了各种微量大麻素在药物使用障碍、焦虑障碍、抑郁障碍、创伤和压力相关障碍、精神障碍、神经发育障碍和饮食失调中的应用。尽管有几篇文章的研究结果不尽相同，而且存在中度到高度的偏倚风险，但某些化合物显示出了进一步研究的前景。Δ8-四氢大麻双甙 (Δ8-THCV)具有治疗尼古丁成瘾的潜力；Δ9-四氢大麻双甙 (Δ9-THCV)具有治疗精神病样症状的潜力；大麻二酚甲酯 (CBDA-ME) 可减轻焦虑和抑郁样症状，大麻双甙 (CBDV) 可减轻自闭症谱系障碍样症状。

{"title":"Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review","authors":"Guido Cammà , Monika P. Verdouw , Pim B. van der Meer , Lucianne Groenink , Albert Batalla","doi":"10.1016/j.euroneuro.2024.10.006","DOIUrl":"10.1016/j.euroneuro.2024.10.006","url":null,"abstract":"<div><div>Interest in cannabinoids’ therapeutic potential in mental health is growing, supported by evidence of the involvement of the endocannabinoid system in psychiatric disorders such as anxiety, depression, and addiction. While the major cannabinoids cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC) have been more extensively researched, approximately 120 minor cannabinoids from the cannabis plant have been identified. Although some displayed promising pharmacological profiles, research on their application for psychiatric disorders is fragmented. This systematic review evaluates, for the first time, both preclinical and clinical studies exploring minor cannabinoids’ therapeutic potential in psychiatric disorders.</div><div>22 preclinical studies and one clinical study were included, investigating various minor cannabinoids in substance use disorders, anxiety disorders, depressive disorders, trauma and stressor-related disorders, psychotic disorders, neurodevelopmental disorders, and eating disorders. Despite the heterogeneous results and the moderate to high risk of bias in several articles, certain compounds demonstrate promise for further investigation. Δ8-tetrahydrocannabidivarin (Δ8‐THCV) exhibited potential for nicotine addiction; Δ9-tetrahydrocannabidivarin (Δ9‐THCV) for psychotic-like symptoms; cannabidiolic acid methyl ester (CBDA-ME) alleviated anxiety and depression-like symptoms, and cannabidivarin (CBDV) autism spectrum disorder-like symptoms.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"Pages 9-24"},"PeriodicalIF":6.1,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Excess mortality and life-years lost in people diagnosed with depression: A 20-year population-based cohort study of 126,573 depressed individuals followed for 1,139,073 persons-years 被诊断为抑郁症患者的超额死亡率和寿命损失：对 126,573 名抑郁症患者进行了长达 20 年、共 1,139,073 人年的人群队列研究。

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2024-11-12 DOI: 10.1016/j.euroneuro.2024.10.009

Heidi Ka Ying Lo , Joe Kwun Nam Chan , Corine Sau Man Wong , Ka Fai Chung , Christoph U Correll , Marco Solmi , Lawrence W Baum , Thuan Quoc Thach , Pak Chung Sham , Wing Chung Chang

Depression is associated with premature mortality, but evidence is mainly derived from Western countries. Very limited research has evaluated shortened lifespan in depression using life-years-lost (LYLs), a recently developed mortality metric taking into account the illness onset for life expectancy estimation. Temporal trends of differential mortality gap are understudied. This population-based cohort study, which utilized a territory-wide medical-record database of public inpatient and outpatient healthcare services in Hong Kong, evaluated the extent of premature mortality in 126,573 individuals with depression (persons-years=1,139,073) between January 2002 and December 2021 regarding the standardized mortality ratio (SMR) and excess LYLs. Trends in annual SMRs over 20 years were assessed by joinpoint analyses. The results showed that individuals with depression exhibited significantly higher all-cause (SMR=1.84 [95% CI=1.82–1.88]), natural-cause (1.69 [1.66–1.72]), and unnatural-cause (5.24 [4.97–5.51]) mortality rates than the general population. Suicide-specific SMR was markedly elevated (7.92 [7.47–8.38]), particularly in the 15–34 year-olds (12.75 [10.87–14.79]). Respiratory diseases, cardiovascular diseases and cancers accounted for the majority of deaths. Excess LYLs extended to men (5.67 years, 95% CI = 5.45–5.90) and women (4.06 years, 95% CI = 3.89–4.23). Overall and natural-cause mortality rates improved over time, but unnatural-cause and suicide-related mortality gaps persisted. Taken together, this study indicates that depression is associated with increased premature mortality and reduced lifespan in a predominantly Chinese population, mainly attributed to natural causes. Relative suicide-specific mortality is substantially elevated, especially among young people. The pronounced mortality gap underscores an urgent need for effective interventions targeting improved physical health and suicide risk reduction in individuals with depression.

抑郁症与过早死亡有关，但证据主要来自西方国家。使用寿命损失年数（LYLs）对抑郁症导致的寿命缩短进行评估的研究非常有限，而寿命损失年数是最近开发的一种死亡率指标，在估算预期寿命时考虑了疾病的发病时间。对不同死亡率差距的时间趋势研究不足。这项以人群为基础的队列研究利用香港公共住院和门诊医疗服务的全港医疗记录数据库，评估了2002年1月至2021年12月期间126,573名抑郁症患者（人年=1,139,073）的过早死亡程度，涉及标准化死亡率（SMR）和超额LYLs。通过连接点分析评估了 20 年间每年 SMR 的趋势。结果显示，抑郁症患者的全因死亡率（SMR=1.84 [95% CI=1.82-1.88]）、自然原因死亡率（1.69 [1.66-1.72]）和非自然原因死亡率（5.24 [4.97-5.51]）明显高于普通人群。自杀的具体 SMR 明显升高（7.92 [7.47-8.38]），特别是在 15-34 岁的人群中（12.75 [10.87-14.79]）。死亡原因主要是呼吸系统疾病、心血管疾病和癌症。男性（5.67 岁，95% CI = 5.45-5.90）和女性（4.06 岁，95% CI = 3.89-4.23）的长寿年限过长。随着时间的推移，总死亡率和自然原因死亡率有所改善，但非自然原因死亡率和自杀相关死亡率的差距依然存在。综上所述，本研究表明，在以中国人为主的人群中，抑郁症与过早死亡率增加和寿命缩短有关，主要归因于自然原因。自杀导致的死亡率相对较高，尤其是在年轻人中。明显的死亡率差距突出表明，迫切需要采取有效干预措施，改善抑郁症患者的身体健康并降低自杀风险。

{"title":"Excess mortality and life-years lost in people diagnosed with depression: A 20-year population-based cohort study of 126,573 depressed individuals followed for 1,139,073 persons-years","authors":"Heidi Ka Ying Lo , Joe Kwun Nam Chan , Corine Sau Man Wong , Ka Fai Chung , Christoph U Correll , Marco Solmi , Lawrence W Baum , Thuan Quoc Thach , Pak Chung Sham , Wing Chung Chang","doi":"10.1016/j.euroneuro.2024.10.009","DOIUrl":"10.1016/j.euroneuro.2024.10.009","url":null,"abstract":"<div><div>Depression is associated with premature mortality, but evidence is mainly derived from Western countries. Very limited research has evaluated shortened lifespan in depression using life-years-lost (LYLs), a recently developed mortality metric taking into account the illness onset for life expectancy estimation. Temporal trends of differential mortality gap are understudied. This population-based cohort study, which utilized a territory-wide medical-record database of public inpatient and outpatient healthcare services in Hong Kong, evaluated the extent of premature mortality in 126,573 individuals with depression (persons-years=1,139,073) between January 2002 and December 2021 regarding the standardized mortality ratio (SMR) and excess LYLs. Trends in annual SMRs over 20 years were assessed by joinpoint analyses. The results showed that individuals with depression exhibited significantly higher all-cause (SMR=1.84 [95% CI=1.82–1.88]), natural-cause (1.69 [1.66–1.72]), and unnatural-cause (5.24 [4.97–5.51]) mortality rates than the general population. Suicide-specific SMR was markedly elevated (7.92 [7.47–8.38]), particularly in the 15–34 year-olds (12.75 [10.87–14.79]). Respiratory diseases, cardiovascular diseases and cancers accounted for the majority of deaths. Excess LYLs extended to men (5.67 years, 95% CI = 5.45–5.90) and women (4.06 years, 95% CI = 3.89–4.23). Overall and natural-cause mortality rates improved over time, but unnatural-cause and suicide-related mortality gaps persisted. Taken together, this study indicates that depression is associated with increased premature mortality and reduced lifespan in a predominantly Chinese population, mainly attributed to natural causes. Relative suicide-specific mortality is substantially elevated, especially among young people. The pronounced mortality gap underscores an urgent need for effective interventions targeting improved physical health and suicide risk reduction in individuals with depression.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"Pages 1-8"},"PeriodicalIF":6.1,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

European Neuropsychopharmacology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀